The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis

BMC Gastroenterology

Research

Toshifumi Ohkusa¹  Hirotaka Kamiya²  Yuichiro Ohtaki²  Yoshihiro Matsumoto²  Kan Uchiyama²  Shigeo Koido²  Yuma Aoki²  Eri Moriizumi²  Sachie Kiryu²  Toshimune Watanabe²  Moe Yamada²  Zensho Ito²  Shizuka Suzuki²  Masayuki Saruta³ 

[1] Department of Microbiota Research, Juntendo University Graduate School of Medicine, 2-1-1 Hongou, 113-8421, Bunkyo-ku, Tokyo, Japan;Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa, 277-8567, Kashiwa-shi, Chiba, Japan;Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, 3-19-18 Nishishinbashi, 105-0003, Minato-ku, Tokyo, Japan;

关键词: Ulcerative Colitis;    MMX;    Bristol Stool Form Scale;    5-ASA;    Adherence;    Multi-matrix system mesalazine;   

DOI  :  10.1186/s12876-022-02474-9

 received in 2022-04-14, accepted in 2022-08-11,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundMulti-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excretion.MethodsThe subjects were 102 UC patients who were newly prescribed MMX alone to induce remission. Their stools were evaluated on the Bristol Stool Form Scale (BSFS), the presence/absence of insoluble MMX excretion was investigated in interviews, and defecation frequency at the start of treatment and disease type were retrospectively investigated by examining their medical records.ResultsThe insoluble excretion rate (IER) was 14.7%. It tended to be higher in the patients with left-sided colitis or extensive colitis, although the differences among the disease types were not significant (p = 0.053). The mean defecation frequency of the patients that reported insoluble MMX excretion was significantly higher than that of the patients that did not report it (6.27 ± 5.28 vs. 3.69 ± 3.17, p < 0.05). The IER tended to be higher among the patients with soft stools (4.5%, 21.9%, and 23.1% in those with BSFS scores of ≤ 4, 5, and ≥ 6, respectively). In ROC analysis of defecation frequency, ≥ 3.5 defecations was found to exhibit sensitivity and specificity of 66.7% and 65.5%, respectively, for predicting insoluble MMX excretion.ConclusionsThe likelihood of insoluble MMX excretion is influenced by defecation frequency and the extent of inflammation. It is important to keep the possibility of insoluble excretion in mind when prescribing MMX.

【 授权许可】

CC BY   
© The Author(s) 2022. corrected publication 2023

【 图 表 】

41116_2022_35_Article_IEq537.gif

Fig. 21

41116_2022_35_Article_IEq481.gif

Fig. 14